Eye Injections and Heart Risk: Is It Serious?
Eye Injections and Heart Risk at a Glance
Talk to your retina specialist before you change anything, and in most cases the answer is that continuing is reasonable. Large studies that pooled thousands of patients have not found that these eye injections, as a group, raise the risk of another stroke or a heart attack. The amount of medicine placed in the eye is tiny next to the doses of similar drugs given into a vein for other diseases. The one real exception is timing. If your stroke was very recent, within the last few months, that is exactly the situation where your eye doctor and your stroke doctor should speak before the next injection. So keep your appointment, share your full health history, and let that team weigh your eyes and your heart together.
The short version is steadying. A 2021 review that combined 74 randomized trials with 23,493 patients found that anti-VEGF eye injections did not increase the risk of major cardiovascular events compared with control treatment.1 An earlier analysis of 13 randomized trials with 4,942 patients also concluded that injecting anti-VEGF medicine into the eye is not linked to a higher risk of clot-related events such as stroke and heart attack.2 It is an average across a group, though, not a promise about any one person, which is why your retina specialist still looks at your own heart history.
For most people on these injections, the heart risk from the drug looks small, and the risk of losing central vision without treatment is often larger. That balance can shift if you have just had a heart attack or stroke, so the decision is personal. Age-related macular degeneration is a common condition and a leading cause of vision loss for older adults.3 Stopping out of fear can let a treatable eye disease steal your sight. Bring your questions, and any recent heart or brain events, to your retina specialist and decide together.
What Anti-VEGF Eye Injections Are and Who Gets Them
Anti-VEGF stands for anti-vascular endothelial growth factor, a medicine that blocks a signal your body uses to grow blood vessels. In several eye diseases, that signal goes into overdrive and makes fragile vessels that leak fluid and blood into the retina. An intravitreal injection places the medicine directly into the vitreous cavity, the jelly-filled space in the back of the eye, and is usually given by a trained retina specialist in the office.4 The anti-VEGF drugs work by reducing the fluid leakage that these disorders cause.4
These injections are used for a handful of retina problems that share one feature: leaking or overgrowing blood vessels. Age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion are the most common conditions treated with intravitreal anti-VEGF drugs.4 In wet, or neovascular, macular degeneration, abnormal blood vessels grow in the back of the eye and damage the macula, the part of the retina you use for sharp central vision.3 Diabetic macular edema is swelling of that same central area in people with diabetes.
A few different anti-VEGF drugs are in common use, and they are more alike than different for most patients. Aflibercept (Eylea) and ranibizumab (Lucentis) are approved by the FDA for wet macular degeneration, while bevacizumab (Avastin) is widely used off-label, meaning for a purpose beyond its original approval. Faricimab (Vabysmo) is a newer anti-VEGF medicine that some people receive on a longer interval. One of the main treatments for wet macular degeneration is an anti-VEGF drug that a doctor injects into the eye.3 Which drug you get depends on your diagnosis, your response, and your retina specialist's judgment.
How the Injection Is Given and How Often
The visit itself is quick, and clinics follow careful steps to keep it safe. Before the injection, the eye is numbed with drops or gel, the eye and eyelids are cleaned with povidone-iodine to kill surface bacteria, and a small clip called an eyelid speculum holds the lids open.4 Cleaning the eye with povidone-iodine before the injection is the single most important step for preventing infection.5 Most people feel pressure or a pinch rather than sharp pain, and the numbing makes it tolerable.
The hardest part for many patients is not one injection but the ongoing series. In long-term conditions like macular degeneration, diabetic macular edema, and vein occlusion, the injections often need to be repeated, with follow-up visits usually about 4 to 6 weeks apart at first.4 Over months and years that adds up to many trips, and it is normal to feel worn down by it. Your specialist may stretch the interval once the disease is calmer. If the burden is wearing on you, say so, because the schedule can often be adjusted.
A heart question exists because no dose stays perfectly sealed inside the eye. A small amount of anti-VEGF medicine can pass from the eye into the bloodstream, so researchers have studied whether it affects the heart and blood vessels. Because the same drug family is given in far larger doses into a vein for other conditions, scientists tested the concern directly. The sections below give what those studies found, in plain numbers.
Side Effects: From a Sore Eye to the Heart Question
Most side effects are local, mild, and short-lived. A small red patch on the white of the eye, called a subconjunctival hemorrhage, can appear where the needle goes in and usually heals within about a week.4 You may notice irritation, watering, or grittiness for a day or two, and some people see a few new floaters. These nuisances are expected and fade, unlike the danger signs described next.
A few complications are uncommon yet important to catch early. Endophthalmitis, a serious infection inside the eye, is rare after an intravitreal injection, with reported rates of roughly 2 to 8 of every 10,000 injections.6 Other rare risks of the injection include a rise in eye pressure, retinal detachment, and bleeding inside the eye.5 The action part matters just as much: increasing pain, growing redness, or dropping vision in the days after an injection is a reason to be seen the same day, because early treatment protects sight.
This is the worry that brings most people to this page, and the honest answer is reassuring without being a blanket promise. The 2021 review of 74 randomized trials found no significant increase in heart attack, stroke, or cardiovascular death with anti-VEGF injections compared with control.1 In that same review, people treated for diabetic retinopathy did show a higher risk of death, a finding researchers are still weighing.1 Because these are averages, not verdicts about you, your own diagnosis and heart history belong in the discussion with your retina specialist.
Who Should Wait or Talk to the Doctor First
Some situations call for pausing rather than proceeding. The aflibercept label states that the injection should not be given when there is an eye or around-the-eye infection, when there is active inflammation inside the eye, or in someone with a known allergy to the drug.7 An eye that is actively inflamed is generally a reason to hold off on an anti-VEGF injection until it settles.5 None of these means you can never be treated. They mean the timing is wrong today, and your retina specialist will reschedule once the eye is calm and safe.
Timing is where individual caution matters most for the heart. A 2023 study found that people who had a heart attack or an ischemic stroke within the 6 months before an injection had a much higher risk of another such event afterward than people without a recent event.8 The authors advised caution before giving these injections to people with a recent heart attack or stroke or with coronary artery disease.8 This does not mean stopping forever. It means that soon after such an event, your eye doctor and your heart or stroke doctor should coordinate on when to resume.
Anti-VEGF drugs block a signal that a developing pregnancy also uses, so pregnancy calls for a careful conversation. The aflibercept label advises women who can become pregnant to use effective birth control before, during, and for at least 3 months after the last injection.7 If you are pregnant, trying to conceive, or breastfeeding, tell your retina specialist so the plan can be adjusted. The point is timing and shared decisions, weighing your eye disease against the pregnancy with both your eye doctor and obstetric team.
Your Real Cardiovascular Risk and Realistic Outlook
Plain numbers help more than vague reassurance. In the wet macular degeneration studies behind the aflibercept label, clot-related events, defined as nonfatal stroke, nonfatal heart attack, or death from a blood-vessel cause, occurred in the first year in 32 of every 1,824 people given aflibercept, close to the 9 of every 595 given ranibizumab.7 Through 96 weeks, these events were reported in 60 of every 1,824 people treated with aflibercept.7 These counts sit near what is expected in older adults who often already have heart risks. Your retina specialist can place your own risk factors against these figures.
A population average cannot tell you your personal outcome, and no honest page will claim it can. The figures above describe large groups, many of whom already had high blood pressure, diabetes, or prior heart disease. Pooled trial evidence does not show that anti-VEGF injections, as a group, raise the risk of stroke or heart attack.2 What that means for you depends on your age, your heart history, and how recent any event was. It is why the safest plan is one your retina specialist tailors to you rather than a single rule for everyone.
Every treatment choice is really a comparison, and the alternative here is rarely harmless. Age-related macular degeneration is a leading cause of vision loss for older adults, and the injections aim to protect the central vision these diseases threaten.3 Left alone, the abnormal blood vessels these drugs target keep damaging the macula that you use for sharp central sight.3 So the question is not risk versus no risk. It is a small, well-studied heart consideration on one side and the real chance of losing central vision on the other, a trade your specialist helps you weigh.
Warning Signs and When to Get Care
Some symptoms after an injection should never wait. Call your eye doctor the same day, or seek urgent eye care, if you notice any of these:
- Eye pain that is new or increasing over the days after the injection
- Growing redness of the eye
- Blurred or decreasing vision, or a sudden drop in sight
- Increasing sensitivity to light
Eye pain, increasing sensitivity to light, or decreased vision after an injection are reasons to contact your eye doctor.4 These can be the first signs of infection inside the eye, and getting seen quickly gives the best chance to protect your vision.
Because this page is about heart and brain safety, know the signs of a stroke too. Stroke warning signs come on suddenly and include numbness or weakness of the face, arm, or leg, especially on one side, sudden confusion or trouble speaking, sudden trouble seeing, sudden trouble walking or loss of balance, and a sudden severe headache.9 The FAST check stands for Face drooping, Arm weakness, Speech difficulty, and Time to call 911, and you should call 911 right away if you notice these signs.9 A stroke is an emergency at any time, whether or not you are due for an injection.
Not every question is an emergency, and knowing who to call saves worry. For eye symptoms like new floaters, pain, or changes in vision, your retina specialist is the right first call. New floaters after the first day should be reported to your eye doctor.4 For heart or blood-pressure concerns, your primary doctor or cardiologist should be in the loop, especially after a recent event. Keeping both teams informed lets them coordinate the timing of your injections around your overall health.
Common Questions About Eye Injections and Heart Risk
Pooled research is reassuring on this point. A 2021 review of 74 randomized trials with 23,493 patients found no significant increase in stroke, heart attack, or cardiovascular death with anti-VEGF injections compared with control.1 A separate meta-analysis of 13 trials reached the same conclusion, finding no link to clot-related events.2 That is strong group evidence, not an individual guarantee. If you have specific heart risks or a recent event, raise them so your plan fits you, not the average.
Do not decide alone, and do not simply skip it without a call. A very recent stroke is the one setting where extra caution is clearly wise. One 2023 study found a much higher risk of a new clot-related event when a heart attack or stroke had happened within the previous 6 months.8 Contact your retina specialist and your stroke doctor and let them coordinate the timing. They may briefly delay, adjust, or proceed with monitoring. The goal is to protect both your brain and your sight, decided together.
A small amount can pass from the eye into the blood, which is the very reason the heart question was studied so carefully. Despite that, pooled trials do not show a higher rate of major cardiovascular events with anti-VEGF injections than with control.1 So the leak is real but tiny, and the measured effect on the heart across large groups has been reassuring. Your specialist can explain how this applies to your own health.
For most patients, the differences are small and not the main driver of the choice. In the wet macular degeneration studies behind the aflibercept label, first-year clot-related events occurred in 32 of every 1,824 people on aflibercept, close to the 9 of every 595 on ranibizumab.7 Those figures are broadly similar. Which drug you receive usually depends on your diagnosis, how your retina responds, and how often you need treatment, more than on heart safety. If you have heart concerns, ask your retina specialist which option fits you best.
In most cases yes, but confirm with the doctor who prescribes it. Blood thinners and aspirin are usually continued for eye injections, since stopping them can carry its own heart and stroke risks. A small subconjunctival hemorrhage, a red patch on the white of the eye, can appear at the injection site and usually clears within about a week.4 That minor bruise is more likely on blood thinners but is not dangerous to the eye. Never stop a heart or stroke medicine on your own; ask the prescribing doctor first.
Stopping can quietly cost you vision, which is the real risk to weigh against a small heart concern. In wet macular degeneration, untreated abnormal blood vessels keep damaging the macula used for sharp central vision.3 If fear is driving the thought of quitting, bring it to your retina specialist rather than acting on it silently. Together you can look at your real heart risk and your real eye risk and choose a plan you can live with.
More Questions Patients Ask
This is a fair question, since the drug family can affect blood vessels. Across large trials the everyday cardiovascular picture has been reassuring. Pooled randomized trials did not show a higher rate of major cardiovascular events with anti-VEGF injections than with control.1 If you already have high blood pressure, keep taking your prescribed medicine and keep your regular checks. Tell your retina specialist and your primary doctor about any big changes in your readings so they can watch the trend and keep both teams aligned.
There is no single answer, because it depends on your disease and your response. In chronic conditions such as macular degeneration, diabetic macular edema, and vein occlusion, injections often need to be repeated, with early follow-up visits usually about 4 to 6 weeks apart.4 Many people start with more frequent visits, then move to longer gaps as the retina stabilizes. Your retina specialist sets and revises the schedule based on your scans and vision, and you can always ask what your own plan looks like.
Often it is a good idea, especially after a recent event or if you have known heart disease. A 2023 study advised caution before giving these injections to people with a recent heart attack or stroke or with coronary artery disease.8 A cardiologist can confirm your heart is stable and coordinate timing with your retina specialist. For people without recent events or major heart disease, routine care with your primary doctor is usually enough. Either way, make sure both teams know you are receiving eye injections.
- Given my heart history, is it safe for me to continue these injections now?
- How recent is too recent after a stroke or heart attack to have an injection?
- Should my cardiologist or stroke doctor and you coordinate on timing?
- Which anti-VEGF medicine am I getting, and why that one for me?
- What eye symptoms after an injection should send me in the same day?
- What is likely to happen to my vision if I pause or stop treatment?
- Can my injection interval be stretched to reduce the burden?
- JAMA Ophthalmology (PubMed Central, National Library of Medicine) (2021). Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
- PLoS One (PubMed Central, National Library of Medicine) (2012). Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events: A Meta-Analysis.
- National Eye Institute (NEI) (2024). Age-Related Macular Degeneration.
- American Society of Retina Specialists (2023). Intravitreal Injections.
- EyeWiki (American Academy of Ophthalmology) (2024). Intravitreal Injections.
- Graefe's Archive for Clinical and Experimental Ophthalmology (PubMed Central, National Library of Medicine) (2022). Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.
- US FDA prescribing information via DailyMed (National Library of Medicine) (2024). EYLEA (aflibercept) injection, US prescribing information.
- Scientific Reports (PubMed Central, National Library of Medicine) (2023). Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections.
- MedlinePlus (National Library of Medicine) (2024). Stroke.